Certara, Inc. (CERT) Q4 Results Fall Short of Expectations

Certara, Inc. Reports Q4 Earnings Below Expectations

Certara, Inc. (CERT) announced quarterly earnings of $0.09 per share, falling short of the Zacks Consensus Estimate of $0.11 per share. In comparison, the company reported $0.15 per share in the same period last year. These results are adjusted to exclude one-time items.

This quarter's earnings represented a negative surprise of 20.57%. In the previous quarter, Certara was anticipated to earn $0.11 per share but actually delivered $0.14, resulting in a positive surprise of 27.27%.

Looking at the past four quarters, Certara has exceeded consensus earnings per share estimates twice.

Within the Zacks Medical - Biomedical and Genetics sector, Certara posted revenue of $103.65 million for the quarter ending December 2025, slightly ahead of the consensus estimate by 0.41%. This marks an increase from $100.36 million in the same quarter last year. Over the last four quarters, the company has surpassed revenue expectations three times.

The immediate impact on Certara’s stock price will likely depend on management’s insights during the earnings call and their outlook for future performance.

Since the start of the year, Certara’s stock has declined approximately 25.2%, while the S&P 500 has gained 1.5% over the same period.

What Lies Ahead for Certara?

Although Certara has trailed the broader market so far this year, investors are now considering what the future holds for the stock.

While there is no definitive answer, one useful indicator is the company’s earnings outlook. This includes not only current consensus estimates for upcoming quarters, but also any recent changes to those projections.

Research indicates a strong link between short-term stock price movements and trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools such as the Zacks Rank, which has a proven track record of leveraging earnings estimate trends.

Prior to this earnings release, Certara’s estimate revisions were trending negatively. Although these trends may shift following the latest report, the current outlook assigns Certara a Zacks Rank #4 (Sell), suggesting the stock may continue to underperform in the near term. For a list of today’s Zacks #1 Rank (Strong Buy) stocks, click here.

It remains to be seen how analyst estimates for the next quarters and the current fiscal year will evolve. Presently, the consensus projects EPS of $0.14 on $110.85 million in revenue for the next quarter, and $0.52 EPS on $449.31 million in revenue for the full fiscal year.

Investors should also consider the broader industry outlook, as it can significantly influence stock performance. The Medical - Biomedical and Genetics industry currently ranks in the top 36% of over 250 Zacks industries. Historically, the top half of Zacks-ranked industries outperforms the bottom half by more than two to one.

Another company in the same sector, Adherex Technologies Inc. (FENC), has yet to announce results for the quarter ending December 2025.

Adherex Technologies is expected to report quarterly earnings of $0.03 per share, which would represent a 150% increase year-over-year. Over the past 30 days, the consensus EPS estimate for the quarter has been raised by 403.6% to its current level.

The company’s revenue is projected to reach $14.97 million, up 88.7% from the same quarter last year.

Is Certara, Inc. (CERT) a Good Investment?

Before deciding to invest in Certara, Inc. (CERT), you may want to explore the top stock picks for the next 30 days. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent research and analytical tools. Over more than 25 years, the Zacks Rank stock-rating system has delivered an average annual return of +24.08%, more than doubling the S&P 500’s performance from January 1, 1988, through May 6, 2024.

Looking for the latest stock recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days for free.